Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Prediabetic Women With Previous Gestational Diabetes.
To investigate the effect of sitagliptin (SITA) and metformin (MET) monotherapy as well as in combination (MET+SITA) on beta-cell function and insulin sensitivity in women with recent gestational diabetes (GDM) and impaired glucose regulation (IGR: IFG and/or IGT). Forty women were randomly assigned to receive SITA (100 mg qd), MET (850 mg bid), or MET+SITA (50+850 mg bid) for 16 weeks. A 75gr OGTT and +125 mg/dl hyperglycemic clamp followed by 5 gr i.v. L-arginine were performed at baseline and study-end. The primary outcome of the study was the mean change in arginine-stimulated insulin secretion rate during the hyperglycemic clamp test from baseline to 16-week therapy RESULTS: At week 16, BMI declined in all groups (-1.2±0.2 Kg/m2 ; p<0.05). MET+SITA gave a greater increase of first phase(2-10 min) insulin secretion and arginine-stimulated response (720.3±299.0 to 995.5±370.3 pmol/l and 3.2±0.6 to 4.8±1.0 pmol/min, respectively, both p<0.05) compared to MET and SITA. Similarly, MET+SITA was more effective in increasing OGTT-based glucose sensitivity (55.7±11.3 to 108±56.2 pmol x min-1 m-2 x mM-1 ; p=0.04) and insulin sensitivity (M/I: 2.2±0.5 to 4.6±1.3 mg/kg/min÷μIU/min/ml; p=0.04; Matsuda Index (SI): 3.1±0.4 to 5.7±1.1; p=0.03) as compared to either MET or SITA. Disposition Index (ISSI-2) increased with MET+SITA and SITA (both p<0.05) while no significant change was observed in MET. Among MET+SITA women, 33% reverted to NGT compared to 14% with MET and 7% with SITA (p<0.05). This study shows that MET+SITA is superior to SITA and MET monotherapy on beta-cell function and insulin sensitivity improvement in IGR women with previous GDM and it may offer a potential pharmacologic intervention to reduce risk of T2D in this high-risk population. This article is protected by copyright. All rights reserved.